Shares of Zydus Lifesciences and Lupin are likely to stay in focus after a key development around Mirabegron, a drug used to treat overactive bladder.
Global pharma major Astellas Pharma, the original innovator of Mirabegron, has raised its revenue guidance for the drug by nearly 80%, signaling strong market demand and growth potential.
During its recent earnings call, Astellas also indicated that it won’t take an aggressive stance on the ongoing patent case related to Mirabegron.
According to CNBC-TV18, this update is seen as a positive read-through for Indian drugmakers Zydus and Lupin, which are among the key players working on or marketing the generic versions of Mirabegron.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
